Q2 EPS Estimates for Nuvectis Pharma Boosted by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at Roth Capital boosted their Q2 2025 earnings estimates for shares of Nuvectis Pharma in a report issued on Tuesday, May 6th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($0.21) per share for the quarter, up from their prior estimate of ($0.26). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.46 EPS and FY2029 earnings at $3.39 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03.

Other analysts also recently issued reports about the stock. Laidlaw initiated coverage on shares of Nuvectis Pharma in a research report on Monday, March 17th. They issued a "buy" rating and a $19.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target (up from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Finally, Maxim Group initiated coverage on shares of Nuvectis Pharma in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 price target on the stock.

Nuvectis Pharma Trading Down 2.5%

Shares of NASDAQ:NVCT traded down $0.23 during mid-day trading on Friday, reaching $8.99. The stock had a trading volume of 121,913 shares, compared to its average volume of 126,703. The firm has a market cap of $212.48 million, a PE ratio of -7.75 and a beta of -0.11. The firm has a 50 day simple moving average of $8.99 and a two-hundred day simple moving average of $7.21. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80.

Institutional Trading of Nuvectis Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Nuvectis Pharma in the fourth quarter valued at approximately $34,000. Nations Financial Group Inc. IA ADV raised its holdings in shares of Nuvectis Pharma by 35.0% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company's stock valued at $73,000 after purchasing an additional 3,500 shares during the last quarter. Baxter Bros Inc. raised its holdings in shares of Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock valued at $81,000 after purchasing an additional 2,500 shares during the last quarter. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma in the first quarter valued at approximately $102,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Nuvectis Pharma in the fourth quarter valued at approximately $103,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 12,444 shares of the stock in a transaction dated Tuesday, May 6th. The shares were bought at an average cost of $8.59 per share, for a total transaction of $106,893.96. Following the completion of the acquisition, the insider now directly owns 2,896,565 shares of the company's stock, valued at approximately $24,881,493.35. This trade represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 35.78% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.